Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

New publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer ...

The early data is particularly significant because CTC clusters are known to be critical mediators of metastasis and markers of poor prognosis. According to Kazia, standard chemotherapy often ...

The global Liquid Biopsy Market is valued at USD 11.41 Billion in 2024 and is projected to reach a value of USD 30.65 Billion ...

Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) saw its stock jump 45% after unveiling preliminary data from the first patient ...

ANGLE plc celebrates 100 peer-reviewed studies validating its Parsortix® system, enhancing cancer diagnostics and personalised treatment strategies.

As per the recent health updates, Shoaib shared that though Dipika has undergone a surgery, there is a high risk of cancer ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary - Cancer rates are rising everywhere ...

Circulating tumor cells mCRPC biomarkers, CTC RNA sequencing prostate cancer, liquid biopsy biomarkers mCRPC, multiomic profiling prostate cancer, PLUVICTO biomarkers, Circulating Tumor Cell ...

Although circulating tumor cells (CTCs) have great potential to act as the mini-invasive liquid biopsy cancer biomarker, a rapid and sensitive CTC detection method remains lacking. CRISPR-Cas12a has ...